ADAM17 and hepatocellular carcinoma: The same group reported the activity of ZLDI-8 as an ADAM17-specific inhibitor able to disrupt the Notch pathway in hepatocellular carcinoma (HCC) cells, avoiding the NICD (Intracellular domain of Notch) accumulation in the nucleus, and inhibiting the EMT process of HCC cells [194].